DrugPatentWatch Database Preview
Patent: 7,824,907
Summary for Patent: 7,824,907
| Title: | Expression vectors comprising the mCMV IE2 promoter |
| Abstract: | The invention relates to an expression vector comprising the promoter of the mCMV-IE2 gene, or a functional expression promoting fragment thereof, and/or an enhancer of the mCMV-IE2 gene, or a functional expression enhancing fragment thereof, wherein expression vector does not contain any complete gene of the mCMV. |
| Inventor(s): | Chatellard; Philippe (Lausanne, CH), Imhof; Markus (Chexbres, CH) |
| Assignee: | Merck Serono SA (Coinsins, Vaud, CH) |
| Application Number: | 10/548,364 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,824,907
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare Pharms | BETASERON | interferon beta-1b | VIAL; SUBCUTANEOUS | 103471 | 001 | 1993-07-23 | Start Trial | Merck Serono SA (Coinsins, Vaud, CH) | 2023-03-11 | RX | Orphan | search |
| Biogen | AVONEX | interferon beta-1a | VIAL | 103628 | 001 | 1996-05-17 | Start Trial | Merck Serono SA (Coinsins, Vaud, CH) | 2023-03-11 | RX | search | |
| Serono Inc | REBIF | interferon beta-1a | SYRINGE | 103780 | 001 | 2002-03-07 | Start Trial | Merck Serono SA (Coinsins, Vaud, CH) | 2023-03-11 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 7,824,907
| Country | Patent Number | Publication Date |
|---|---|---|
| Austria | 399872 | Jul 15, 2008 |
| Australia | 2004219917 | Jan 31, 2008 |
| Australia | 2004219917 | Sep 23, 2004 |
| >Country | >Patent Number | >Publication Date |
